Immatics receives final 22m Euro Tranche of Series D funding
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged 2015, BioRN, finance, funding, Germany, IMA901, immatics, Munich Biotech, oncology, Paul Higham, phase III clincial studies, RCC, renal cell carcinoma, Series D, Wellington Partners, XPRESIDENT
Leave a comment
UK Government names biotech veteran Minister for Life Sciences
Authored by James Sheppard
Posted in Executive Appointments, M&A Finance and Funding, Pharmaceutical business
Tagged AbbVie, AstraZeneca, Britain, George Freeman, London Biotech, medical research, Merlin Biosciences, Minister for Life Sciences, NHS, One Nucleus, Oxford Biotech, Pfizer, Shire, Stevenage Biotech, Takeda, UK, UK government
Leave a comment
Loxo Oncology Expands Leadership Team
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases, Recruitment Market
Tagged Aisling Capital, biopharmaceutical, CFO, Cluster, Corporate Strategy, development, Dov Goldstein, Erivedge, EVP research & Development, executive recrutiment, Genentech, Jacob Van Naarden, Jennifer Low, Loxo Oncology, New York, research, USA, Vic President, Vicuron
Leave a comment
Novartis and Google collaborate to develop ‘Smart Contact Lenses’
Authored by James Sheppard
Gene Therapy used to create biological pacemakers
Authored by James Sheppard
Wales Launches Life Science Hub in Cardiff
Authored by James Sheppard
Prosensa announces senior management and board appointments
Authored by Karl Simpson
Posted in Executive Appointments, Orphan Drugs and Rare Diseases, Recruitment Market
Tagged Annalisa jenkins, Board of Directors, Chief Commerical Officer, DMD, Duchenne Muscular Dytrophy, Genzyme, GSK, Merck Serono, Prosensa, R&D, research and development, to-BBB, Willem W. van Weperen
Leave a comment
Executive Recruitment Roundup – July
Authored by Liftstream
Posted in Executive Appointments, Recruitment Market
Tagged Abingworth, ARIAD Pharmaceuticals, Baxter BioScience, board appointment, Boston Therapeutics, Cary Pfeffer, CEO, Chief Medical Officer, executive appointment, Glide Pharma, John Orloff, Jounce Therapeutics, Ken Hass, Louis O'Dea, Marck Voigrt, Merck Serono, Moderna Therapeutics, Oxford Immunotec, QChip, Radius health, regulatory affairs, Richard Bungay, Richard Murray, Robert Pietrusko, Shire, Third Rock Ventures, Timothy Haines, Tony Mills, Vin Miles, Viropharma, Voyager Therpaeutics, Yan Moore
Leave a comment
